do glp 1 not work for some people One in 10 may have resistance to GLP-1 diabetes drugs Research, including new findings published

Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes

10.1186/s13075-018-1660-6 282

Blood-Brain Barrier Penetration and CNS Distribution Achieving sufficient CNS concentrations is a critical pharmacokinetic requirement for a procognitive compound, and Dihexa's peptidomimetic design addresses this challenge

The question is: how do we optimize ECS-targeting therapies to treat seizures, pain, neuroprotection, and appetite dysregulation across indications

The acetyl group in ALCAR improves its ability to cross the blood-brain barrier, acting as a potent antioxidant

The pore size can be adjusted and enlarged by varying the activation time and processing temperature